Gilead presents positive data on liver fibrosis treatments

18 April 2016

US biotech Gilead Sciences (Nasdaq: GILD) has presented new data showing positive signs on treatments it is developing for the liver conditions nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).

The findings, which were presented at the International Liver Congress 2016 in Barcelona, Spain, support the continuation of studies of simtuzumab, GS-4997 and GS-9674, investigational compounds for the treatment of NASH and PSC.

NASH is a serious liver disease resulting from metabolic dysfunction that is associated with steatosis – fat within the liver – along with inflammation and fibrosis, which may progress to cirrhosis. By 2020, NASH-related cirrhosis is expected to become the leading indication for liver transplantation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK